Moneycontrol PRO

business

Biocon Q1 net seen down 5%, contract research may drive revenue

Factors to watch out for in Q1 would be margin, contract research business, R&D cost, pricing pressure in legacy API biz (especially statins), recovery in branded formulation (was flat in Q4 due to restructuring) and pick up in Middle East market (did well in Q4).

LATEST VIDEOS

Watch More →

A collection of the most-viewed Moneycontrol videos.

Watch and Follow our leading shows

Sections
ISO 27001 - BSI Assurance Mark